Most of the above mentioned effects appear to be due to the pharmacological activity of irbesartan (blockade of angiotensin-II-induced inhibition of renin release, with stimulation of the renin-producing cells) and occur also with angiotensin converting enzyme inhibitors.
Enamus ülaltoodud toimeid tekib irbesartaani farmakoloogilise aktiivsuse tõttu (AT- II- tekitatud reniini vabanemise inhibeerimise pärssimine, koos reniini tootvate rakkude stimulatsiooniga) ja ilmneb samuti AKE inhibiitoritega.